Illumina, Inc. (ILMN) has a MoatMap StockRank of 84/100 based on Quality (73/100), Value (28/100), and Momentum (68/100) factor scores. The current signal is STRONG BUY. Illumina is the dominant player in gene sequencing, but it is currently a complex corporate turnaround story following the disastrous and costly Grail acquisition. This violates our Terry Smith rule of avoiding turnarounds and broken capital allocation stories.
Illumina, Inc. is the global leader in developing, manufacturing, and marketing integrated systems for large-scale analysis of genetic variation and function, providing sequencing and array-based instruments, reagents, and services. The company's formidable competitive moat stems from its proprietary sequencing technology, superior data quality, and extensive patent portfolio, which have established its platforms as the industry standard for genomic research and clinical applications worldwide. This dominant market position makes Illumina essential to advancements in precision medicine and biotechnology.
| Price | $160.03 |
| Market Cap | $24.0B |
| P/E (TTM) | 30.56 |
| P/E (Forward) | 28.38 |
| Price/Book | 9.55 |
| Return on Equity | 33.8% |
| Return on Invested Capital | 23.5% |
| Debt/Equity | 95.07 |
| Gross Margin | 68.3% |
| Operating Margin | 18.3% |
| Revenue Growth | 4.8% |
| Free Cash Flow | $846M |
Illumina, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).